-
Infection Rate and Risk Factors of SARS-CoV-2 Infection Among Retail Workers
-
Impact of the COVID-19 Pandemic on the Detection of Leprosy in High Risk of Illness in Minas Gerais, Brazil
-
Multidisciplinary Approach of a Male Case of Imported Malaria, HIV Chronic Infection, and Latent Syphilis
-
Using T-Cell Subsets to Better Characterize Immunoresiliency and Immunodeficiency in Patients with Recurrent Infections
Journal Description
Infectious Disease Reports
Infectious Disease Reports
is an international, scientific, peer-reviewed open access journal on infectious diseases published bimonthly online by MDPI (from Volume 12 Issue 3 - 2020).
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 32.4 days after submission; acceptance to publication is undertaken in 3.9 days (median values for papers published in this journal in the second half of 2024).
- Journal Rank: JCR - Q2 (Infectious Diseases) / CiteScore - Q2 (Infectious Diseases)
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
- Benefits of Publishing: We aim to be a leading journal on infectious diseases and to be in the top 20 journals listed in the Journal Citation Report (JCR) in this specific category in the near future.
Impact Factor:
3.4 (2023);
5-Year Impact Factor:
3.0 (2023)
Latest Articles
Advances in the Management of Infectious Diseases
Infect. Dis. Rep. 2025, 17(2), 26; https://doi.org/10.3390/idr17020026 - 14 Mar 2025
Abstract
The landscape of infectious diseases has dramatically evolved since the 1970s and the advent of antimicrobials, which heralded a new era in medical history [...]
Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Infectious Diseases)
Open AccessArticle
Unhealthy Food Consumption Is Associated with Post-Acute Sequelae of COVID-19 in Brazilian Elderly People
by
Guilherme José Silva Ribeiro, Rafaela Nogueira Gomes de Morais, Olufemi Gabriel Abimbola, Nalva de Paula Dias, Mariana De Santis Filgueiras, André de Araújo Pinto and Juliana Farias de Novaes
Infect. Dis. Rep. 2025, 17(2), 25; https://doi.org/10.3390/idr17020025 - 13 Mar 2025
Abstract
►▼
Show Figures
Background/Objectives: The factors associated with post-acute sequelae of COVID-19 (PASC) are not yet fully understood in developing countries. Our objective was to investigate the relationship between food consumption and the occurrence of PASC in Brazilian elderly people. Methods: This cross-sectional study
[...] Read more.
Background/Objectives: The factors associated with post-acute sequelae of COVID-19 (PASC) are not yet fully understood in developing countries. Our objective was to investigate the relationship between food consumption and the occurrence of PASC in Brazilian elderly people. Methods: This cross-sectional study included 1322 elderly people aged 60 or over, infected with SARS-CoV-2 in 2020, living in the state of Roraima in Brazil. Using the Brazilian National Food and Nutrition Surveillance System (SISVAN, in Portuguese) tool, food consumption markers were evaluated. The persistence of post-acute sequelae of COVID-19 was assessed three months after SARS-CoV-2 infection. Poisson regression with robust variance was performed to estimate the prevalence ratio (PR) with a 95% confidence interval (95% CI). Results: Fruit consumption [PR 0.92; 95% CI: 0.85–0.99] was associated with a lower occurrence of PASC, with a significant interaction in individuals aged 60 to 69 years old, not hospitalized, and those without chronic kidney disease. In addition, the consumption of sugar-sweetened beverages [PR 1.23; 95% CI: 1.12–1.35], sandwich cookies, sweets, and treats [PR 1.12; 95% CI 1.03–1.22] was positively associated with the occurrence of PASC in the elderly people, with a significant interaction in individuals living in the capital and without hypercholesterolemia. Conclusions: Unhealthy food consumption was associated with PASC in Brazilian elderly people. An improvement in the diet quality of elderly people is necessary to minimize health complications in PASC.
Full article

Figure 1
Open AccessEditorial
Phage Therapy for Mycobacteria: Overcoming Challenges, Unleashing Potential
by
Christoffel Johannes Opperman and Adrian J. Brink
Infect. Dis. Rep. 2025, 17(2), 24; https://doi.org/10.3390/idr17020024 - 12 Mar 2025
Abstract
Bacteriophage (phage) therapy is emerging as a promising alternative to traditional antibiotics for treating drug-resistant mycobacterial infections, including Mycobacterium tuberculosis complex (MTBC) and non-tuberculous mycobacteria (NTM) [...]
Full article
Open AccessCase Report
Syphilitic Cholangiopathy Mimicking Primary Sclerosing Cholangitis
by
Adriana Gregušová, Michal Gergel and Miroslav Žigrai
Infect. Dis. Rep. 2025, 17(2), 23; https://doi.org/10.3390/idr17020023 - 6 Mar 2025
Abstract
Introduction: Syphilis is a sexually transmitted disease with variable symptoms, often imitating various other disorders. Syphilis progresses through primary, secondary, latent, and tertiary stages, each with distinct clinical manifestations. A sudden rise in serum hepatic enzyme levels and imaging findings that mimic sclerosing
[...] Read more.
Introduction: Syphilis is a sexually transmitted disease with variable symptoms, often imitating various other disorders. Syphilis progresses through primary, secondary, latent, and tertiary stages, each with distinct clinical manifestations. A sudden rise in serum hepatic enzyme levels and imaging findings that mimic sclerosing cholangitis, both associated with a positive response to targeted antibiotic treatment, may indicate a diagnosis of acute syphilitic hepatitis. Case Presentation: We report a case of early syphilis in the secondary stage, manifesting as sclerosing-cholangitis-like changes shown on ultrasonography, MR, and CT. Narrow-spectrum antibiotic therapy with procaine benzylpenicillin led to a consistent decrease in and normalization of levels of serum bilirubin and other markers of hepatic injury. Repeated sonography and MR cholangiography showed minimal residual changes in the intrahepatic biliary tree. Conclusions: Infection with Treponema pallidum is one of the rare causes of secondary cholangitis. As the incidence of syphilis is rising worldwide, it should be considered as a differential diagnosis, especially for patients with high-risk sexual behavior and for whom there are laboratory findings of cholestatic or mixed cytolytic and cholestatic hepatitis, particularly if associated with exanthema, pharyngitis, and lymphadenopathy.
Full article
(This article belongs to the Section Sexually Transmitted Diseases)
►▼
Show Figures

Figure 1
Open AccessSystematic Review
Clinical, Functional, and Hemodynamic Profile of Schistosomiasis-Associated Pulmonary Arterial Hypertension Patients in Brazil: Systematic Review and Meta-Analysis
by
Camila M. C. Loureiro, André L. Scheibler Filho, Vitor M. A. S. Menezes, Ricardo A. Correa, Rudolf K. F. Oliveira, Claudia Mickael, Joan F. Hilton and Brian B. Graham
Infect. Dis. Rep. 2025, 17(2), 22; https://doi.org/10.3390/idr17020022 - 4 Mar 2025
Abstract
Background: Schistosoma-associated pulmonary arterial hypertension (Sch-PAH), a complication of hepatosplenic schistosomiasis, is still underdiagnosed and undertreated. Sch-PAH is the third-most common cause of pulmonary arterial hypertension (PAH) in Brazil, and it is estimated that there are around 60,000 afflicted individuals. However, there is
[...] Read more.
Background: Schistosoma-associated pulmonary arterial hypertension (Sch-PAH), a complication of hepatosplenic schistosomiasis, is still underdiagnosed and undertreated. Sch-PAH is the third-most common cause of pulmonary arterial hypertension (PAH) in Brazil, and it is estimated that there are around 60,000 afflicted individuals. However, there is a lack of data on these patients, especially in endemic areas. Therefore, this study aimed to describe baseline demographic data, hemodynamic severity of disease, and functional impairment of Sch-PAH patients at diagnosis. Methods: For this systematic review, five databases (Embase, PubMed, SciELO, LILACS, and Cochrane) were searched to identify candidate publications reporting clinical, hemodynamic, and functional data at diagnosis of Sch-PAH patients referred to a PAH reference center in Brazil. Studies were excluded if they enrolled patients under the age of 18, the diagnosis was not confirmed by right heart catheterization (RHC), consisted of case reports, or did not report original data. Risk of bias was assessed using the Newcastle–Ottawa Scale and an adapted version for cross-sectional studies. Single-arm meta-analysis with a random-effect model was performed for each variable. Results: From 459 studies identified through systematic database searching, five studies were selected for this meta-analysis. The majority of the included patients were women (67%), New York Heart Association (NYHA) functional class III/IV (57%), mean age 49 years (95% confidence interval [95% CI], 46–52), 6 min walk distance 392 m (95% CI, 291–493), mean pulmonary arterial pressure (mPAP) 59 mmHg (95% CI, 56–61), pulmonary vascular resistance (PVR) 12 WU (95% CI, 11–13) and cardiac index (CI) 2.57 L/min/m2 (95% CI, 2.25–2.88). Conclusions: In summary, Sch-PAH has clinical characteristics similar to other forms of PAH, including connective tissue disease and idiopathic PAH. Additional studies or a unified registry would be essential for a better understanding of this relevant disease in Brazil.
Full article
(This article belongs to the Section Infection Prevention and Control)
►▼
Show Figures

Figure 1
Open AccessArticle
Endothelial Dysfunction Markers Correlate with the Time Since Completion of Tuberculosis Treatment and the Number of Previous Tuberculosis Episodes
by
Chrisstoffel Jumaar, Steve Jacobs, Carmen Payne, Olakunle Sanni, Elize Louw, Nicola Baines, David Maree, Benjamin Botha, Merga Belina Feyasa, Hans Strijdom, Brian Allwood and Gerald J. Maarman
Infect. Dis. Rep. 2025, 17(2), 21; https://doi.org/10.3390/idr17020021 - 28 Feb 2025
Abstract
Background: Despite “successful” treatment, some lung tuberculosis (TB) patients develop long-term lung impairments that includes damage to the parenchyma and reduced function, which may predispose them to diseases like pulmonary hypertension. However, this is not well understood. Therefore, we investigated whether previous or
[...] Read more.
Background: Despite “successful” treatment, some lung tuberculosis (TB) patients develop long-term lung impairments that includes damage to the parenchyma and reduced function, which may predispose them to diseases like pulmonary hypertension. However, this is not well understood. Therefore, we investigated whether previous or current TB patients would display elevated biomarkers of endothelial dysfunction and vascular remodeling. Methods: We performed assays for ADMA, VCAM-1, VEGF, angiopoietin-1, TBARS, NT-pro-BNP, and cardiac troponin-I. We further stratified the patients based on 1, 2, 3, and >3 previous TB episodes, and 1–5 yrs, 5–10 yrs, 10–15 yrs and >15 yrs after the last TB treatment completion. We also assessed correlations between the biomarkers and the number of previous TB episodes or the time since the completion of the last TB treatment. Results: ADMA was 70 times higher, VEGF was 2000 times higher and angiopoietin-1 was 6500 times higher than the normal range. NT-pro-BNP and cardiac troponin-I were undetected, and TBARS levels were low. There was a positive linear relationship between the number of previous TB episodes and angiopoietin-1, and between VEGF and the number of previous TB episodes. ADMA, VCAM-1 and TBARS exhibited a weak and negative linear association with the number of previous TB episodes. A negligible negative linear association was observed between the time since the completion of the last TB treatment and angiopoietin-1, VEGF and ADMA. Conclusions: Therefore, having >1 previous TB episode, despite the successful completion of TB treatment, associates with an increased risk of endothelial dysfunction/angiogenesis or vascular remodeling.
Full article
(This article belongs to the Special Issue Pulmonary Vascular Manifestations of Infectious Diseases)
Open AccessArticle
Comprehensive Analysis of Influenza Viruses’ Trends in Italy: Insights from a Nationwide and Regional Perspective
by
Francesco Branda , Nicola Petrosillo , Dong Keon Yon , Massimo Ciccozzi and Fabio Scarpa
Infect. Dis. Rep. 2025, 17(2), 20; https://doi.org/10.3390/idr17020020 - 27 Feb 2025
Abstract
►▼
Show Figures
Background. Influenza remains a significant public health issue, with seasonal trends varying across regions. This study provides a comprehensive analysis of influenza virus trends in Italy, leveraging epidemiological and virological data from the Istituto Superiore di Sanità (ISS). The primary objective is
[...] Read more.
Background. Influenza remains a significant public health issue, with seasonal trends varying across regions. This study provides a comprehensive analysis of influenza virus trends in Italy, leveraging epidemiological and virological data from the Istituto Superiore di Sanità (ISS). The primary objective is to assess influenza activity at both national and regional levels, highlighting variations in incidence rates and viral subtype circulation during the 2023/2024 season. Methods. We conducted a systematic approach to data collection, processing, and visualization, utilizing influenza surveillance data from ISS. Incidence rates, subtype distribution, and co-circulating respiratory viruses were analyzed to identify key trends. Results. Our findings reveal a significant increase in influenza cases during the 2023/2024 season, with incidence rates surpassing pre-pandemic levels. Notably, changes in the circulation of influenza A(H3N2) and influenza B were observed, alongside the presence of other respiratory viruses such as RSV and rhinovirus. Conclusions. This study underscores the importance of real-time surveillance, transparent data sharing, and advanced visualization tools in guiding public health responses. By integrating lessons from COVID-19, we highlight the necessity of standardized surveillance frameworks to enhance preparedness for future seasonal outbreaks and potential pandemics.
Full article

Figure 1
Open AccessReview
COVID-19 and Parasitic Co-Infection: A Hypothetical Link to Pulmonary Vascular Disease
by
Peter S. Nyasulu, Jacques L. Tamuzi, Rudolf K. F. Oliveira, Suellen D. Oliveira, Nicola Petrosillo, Vinicio de Jesus Perez, Navneet Dhillon and Ghazwan Butrous
Infect. Dis. Rep. 2025, 17(2), 19; https://doi.org/10.3390/idr17020019 - 27 Feb 2025
Abstract
Background/Objectives: Before the Coronavirus disease 2019 (COVID-19) era, the global prevalence of pulmonary arterial hypertension (PAH) was between 0.4 and 1.4 per 100,000 people. The long-term effects of protracted COVID-19 associated with pulmonary vascular disease (PVD) risk factors may increase this prevalence.
[...] Read more.
Background/Objectives: Before the Coronavirus disease 2019 (COVID-19) era, the global prevalence of pulmonary arterial hypertension (PAH) was between 0.4 and 1.4 per 100,000 people. The long-term effects of protracted COVID-19 associated with pulmonary vascular disease (PVD) risk factors may increase this prevalence. According to preliminary data, the exact prevalence of early estimates places the prevalence of PVD in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 22%, although its predictive value remains unknown. PVD caused by COVID-19 co-infections is understudied and underreported, and its future impact is unclear. However, due to COVID-19/co-infection pathophysiological effects on pulmonary vascularization, PVD mortality and morbidity may impose a genuine concern—both now and in the near future. Based on reported studies, this literature review focused on the potential link between COVID-19, parasitic co-infection, and PVD. This review article also highlights hypothetical pathophysiological mechanisms between COVID-19 and parasitic co-infection that could trigger PVD. Methods: We conducted a systematic literature review (SLR) searching peer-reviewed articles, including link between COVID-19, parasitic co-infection, and PVD. Results: This review hypothesized that multiple pathways associated with pathogens such as underlying schistosomiasis, human immunodeficiency virus (HIV), pulmonary tuberculosis (PTB), pulmonary aspergillosis, Wuchereria bancrofti, Clonorchis sinensis, paracoccidioidomycosis, human herpesvirus 8, and scrub typhus coupled with acute or long COVID-19, may increase the burden of PVD and worsen its mortality in the future. Conclusions: Further experimental studies are also needed to determine pathophysiological pathways between PVD and a history of COVID-19/co-infections.
Full article
(This article belongs to the Special Issue Pulmonary Vascular Manifestations of Infectious Diseases)
►▼
Show Figures

Figure 1
Open AccessArticle
Utilizing an Educational Intervention to Enhance Influenza Vaccine Literacy and Acceptance Among Minoritized Adults in Southern Californian Vulnerable Communities in the Post-COVID-19 Era
by
Jacinda C. Abdul-Mutakabbir, Raheem Abdul-Mutakabbir and Samuel J. Casey
Infect. Dis. Rep. 2025, 17(2), 18; https://doi.org/10.3390/idr17020018 - 26 Feb 2025
Abstract
►▼
Show Figures
Background/Objectives: Since the COVID-19 pandemic began, vaccination rates for preventable diseases, including influenza, have significantly dropped among racially and ethnically minoritized (REM) individuals in the United States. This study explored the effects of a community-based educational intervention designed to improve influenza vaccine literacy
[...] Read more.
Background/Objectives: Since the COVID-19 pandemic began, vaccination rates for preventable diseases, including influenza, have significantly dropped among racially and ethnically minoritized (REM) individuals in the United States. This study explored the effects of a community-based educational intervention designed to improve influenza vaccine literacy and acceptance among vulnerable REM individuals. Methods: The intervention included four 45 min interactive educational sessions on the influenza vaccine. The session attendees (18+) were invited to participate in a pre-/post-intervention study where an anonymous survey measured their post-COVID-19 pandemic attitudes, knowledge, and behaviors regarding the influenza virus and vaccine. To assess the effect of the intervention on vaccine literacy, we used a Mann–Whitney U test to test for differences between the pre-/post-intervention survey responses to seven knowledge-based questions. Descriptive statistics were employed to assess the impact of intervention on vaccine acceptance. Results: A total of 116 participants completed the pre-intervention survey, and 90 (78%) completed the post-intervention survey. All (100%) identified as REM, and 99% lived in highly vulnerable areas. Only 43% believed they were at risk for viral infection before the intervention, but 60% said the intervention helped them reassess their risk. We found significant differences in vaccine literacy when comparing the pre-/post-intervention survey responses, particularly regarding guideline-based vaccine recommendations (p < 0.05). Before the intervention, 65% of the participants indicated a high likelihood of receiving the influenza vaccine. In contrast, after the intervention, 81% of respondents indicated a high likelihood of being vaccinated, and 72% indicated that they were “extremely likely” to receive the immunization. Conclusions: Community-based educational interventions can have a positive impact on influenza vaccine literacy and acceptance among vulnerable REM populations in the post-COVID-19 era.
Full article

Figure 1
Open AccessArticle
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection
by
Giovanna Travi, Francesco Peracchi, Marco Merli, Emanuele Ravano, Anna Frustaci, Marina Deodato, Diana Fanti, Alice Nava, Valeriana Colombo, Nicholas Brian Bana, Carlotta Rogati, Alessandro Raimondi, Cristina Moioli, Anna Maria Pazzi, Marta Vecchi, Davide Motta, Roberto Rossotti, Chiara Oltolini, Fulvio Crippa, Enrico Minetti, Chiara Vismara, Roberto Cairoli and Massimo Puotiadd
Show full author list
remove
Hide full author list
Infect. Dis. Rep. 2025, 17(2), 17; https://doi.org/10.3390/idr17020017 - 26 Feb 2025
Abstract
Background: Immunosuppressed patients still exhibit a high mortality rate due to SARS-CoV-2 infection, up to 21%. Persistent viral load replication and protracted viral symptoms result in a high risk of developing pneumonia, a potential risk of antiviral resistance, and a subsequent delay of
[...] Read more.
Background: Immunosuppressed patients still exhibit a high mortality rate due to SARS-CoV-2 infection, up to 21%. Persistent viral load replication and protracted viral symptoms result in a high risk of developing pneumonia, a potential risk of antiviral resistance, and a subsequent delay of onco-hematological treatments. Methods: Hematological patients and kidney transplant patients with SARS-CoV-2 infection, treated at GOM Niguarda Hospital (Milan) with combined antiviral therapy (remdesivir plus nirmatrelvir/ritonavir at standard doses) between November 2022 and March 2024, were retrospectively reviewed. Results: Thirty-four patients were analyzed. Twenty-four (71%) patients had pneumonia. The median duration of SARS-CoV-2 positivity before antiviral treatment was 40 (10–34) days. The median treatment duration was 11 (10–10) days. All patients went through clinical resolution. Thirteen patients were exposed to a new immune-chemotherapy cycle early after antiviral treatment (median 13, IQR 6–12 days), while five resumed a standard immunosuppressive regimen immediately after viral clearance. No relapse or recurrence of symptoms was reported for up to 226 (106–318) days of follow-up. Antiviral therapy was well tolerated, and no adverse events were observed. The 30-day overall survival was 94%, while the 90-day survival was 88%. No patient died of SARS-CoV-2 infection. Conclusions: The administration of nirmatrelvir/ritonavir and remdesivir lead to the complete resolution of SARS-CoV-2 pneumonia with no side effects in this cohort. The combination of these two antivirals may be a safe option in immunosuppressed population at risk of severe complications and prolonged SARS-CoV-2 infection in order to treat severe clinical presentation and to avoid viral recurrence after chemotherapy.
Full article
(This article belongs to the Section Viral Infections)
►▼
Show Figures

Figure 1
Open AccessArticle
Imported Typhoid Fever in Romania Between 2010 and 2024
by
Dragos Stefan Lazar, George Sebastian Gherlan, Simin Aysel Florescu, Corneliu Petru Popescu and Maria Nica
Infect. Dis. Rep. 2025, 17(2), 16; https://doi.org/10.3390/idr17020016 - 25 Feb 2025
Abstract
►▼
Show Figures
Background/Objectives: Although a “forgotten” disease in developed countries, typhoid fever remains a significant global health problem, especially in regions with inadequate sanitation and overcrowding. Despite medical advances, this systemic bacterial infection, caused by Salmonella Typhi, continues to affect millions worldwide. Accurate diagnosis and
[...] Read more.
Background/Objectives: Although a “forgotten” disease in developed countries, typhoid fever remains a significant global health problem, especially in regions with inadequate sanitation and overcrowding. Despite medical advances, this systemic bacterial infection, caused by Salmonella Typhi, continues to affect millions worldwide. Accurate diagnosis and timely treatment are crucial to prevent severe complications and mortality. Even though antibiotic therapy is effective, the emergence of drug-resistant strains is a growing challenge. Methods: We present a series of cases encountered in a tertiary infectious disease hospital in Romania over 15 years. Results: The hospitalised patients were mainly from Sub-Saharan Africa and the Indian subcontinent; the median time between the onset of the first symptoms and hospital admission was 15 days. The symptoms encountered along with fever were headache, chills, cough, diarrhoea and tachycardia, an unusual feature in the clinical picture of this disease. Aneosinophilia (the absence of peripheral eosinophilic granulocytes) was the most frequently encountered laboratory finding, followed by increased serum transaminases and inflammatory syndrome. Conclusions: S. Typhi was generally identified from blood culture, demonstrating, except in one case, resistance to ciprofloxacin and, in several cases, multi-drug resistance (MDR). In this series of cases, all strains were sensitive to ceftriaxone.
Full article

Figure 1
Open AccessReview
Genetics of Long COVID: Exploring the Molecular Drivers of Persistent Pulmonary Vascular Disease Symptoms
by
Sana Ayyoub, Navneet Kaur Dhillon and Olga Tura-Ceide
Infect. Dis. Rep. 2025, 17(1), 15; https://doi.org/10.3390/idr17010015 - 13 Feb 2025
Abstract
Background/ Objectives: Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC) are symptoms that manifest despite passing the acute infection phase. These manifestations encompass a wide range of symptoms, the most common being fatigue, shortness of breath, and cognitive dysfunction. Genetic predisposition is
[...] Read more.
Background/ Objectives: Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC) are symptoms that manifest despite passing the acute infection phase. These manifestations encompass a wide range of symptoms, the most common being fatigue, shortness of breath, and cognitive dysfunction. Genetic predisposition is clearly involved in the susceptibility of individuals to developing these persistent symptoms and the variation in the severity and forms. This review summarizes the role of genetic factors and gene polymorphisms in the development of major pulmonary vascular disorders associated with long COVID. Methods: A comprehensive review of current literature was conducted to examine the genetic contributions to pulmonary complications following SARS-CoV-2 infection. Studies investigating genetic polymorphisms linked to pulmonary hypertension, pulmonary thromboembolism, and pulmonary vascular endothelialitis were reviewed and summarized. Results: Findings show that specific genetic variants contribute to increased susceptibility to pulmonary vascular complications in long COVID patients. Variants associated with endothelial dysfunction, coagulation pathways, and inflammatory responses have been implicated in the development of pulmonary hypertension and thromboembolic events. Genetic predispositions influencing vascular integrity and immune responses appear to influence disease severity and progression. Conclusions: Understanding these mechanisms and genetic predispositions could pave the way for targeted therapeutic interventions to alleviate the burden on patients experiencing long COVID.
Full article
(This article belongs to the Special Issue Pulmonary Vascular Manifestations of Infectious Diseases)
Open AccessCase Report
Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
by
Eleonora Francesca Pattonieri, Marilena Gregorini, Maria Antonietta Grignano, Tefik Islami, Gioacchino D’Ambrosio, Gianluigi Ardissino and Teresa Rampino
Infect. Dis. Rep. 2025, 17(1), 14; https://doi.org/10.3390/idr17010014 - 11 Feb 2025
Abstract
Case Report: We report a case of a 37-year-old female with kidney transplant, who was admitted at our hospital due to worsening renal function, nephrotic proteinuria, and anemia developed 21 days after the second dose of BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Laboratory tests revealed
[...] Read more.
Case Report: We report a case of a 37-year-old female with kidney transplant, who was admitted at our hospital due to worsening renal function, nephrotic proteinuria, and anemia developed 21 days after the second dose of BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Laboratory tests revealed hemolytic anemia, thrombocytopenia, and acute kidney injury. Given the clinical picture of Thrombotic Micro-angiopathy (TMA) and severe renal impairment, plasma exchange (PEX) and dialysis were immediately started. Laboratory workup showed low C3 and C4 levels, normal activity of ADAMTS13, and the absence of anti-factor H antibodies. Molecular biology investigations revealed a heterozygous variant in exon 22 (SCR20) of the CFH gene (c.3628C>T; p.Arg1210Cys) described as an atypical Hemolytic Uremic Syndrome (aHUS) causative mutation. Our patient completed two sessions of PEX followed by eculizumab treatment with hematological improvement but no recovery of renal function. This is the first reported case of aHUS triggered by SARS-CoV-2 vaccination in a kidney transplant patient without recovery of renal function. Conclusion: Although rare, clinicians should be aware of possible nephrological complications that may appear after vaccination.
Full article
(This article belongs to the Section Immunology and Vaccines)
►▼
Show Figures

Figure 1
Open AccessCase Report
A Report of Two Uncommon Cases of Mycobacterium chelonae with Localized and Disseminated Skin and Soft Tissue Infection
by
Libardo Rueda Prada, Marko Gorasevic, Tatjana Gavrancic, Aayushi J. Rajani, Jason C. Sluzevich, Sangeeta Nair-Collins and Ravi V. Durvasula
Infect. Dis. Rep. 2025, 17(1), 13; https://doi.org/10.3390/idr17010013 - 8 Feb 2025
Abstract
Background: Mycobacterium chelonae is a ubiquitous, rapidly growing, nontuberculous mycobacteria that primarily affects immunocompromised patients. The most common presentation is an atypical, chronic skin and soft tissue infection. Due to its high resistance rate, early diagnosis based on clinical suspicion, risk factor
[...] Read more.
Background: Mycobacterium chelonae is a ubiquitous, rapidly growing, nontuberculous mycobacteria that primarily affects immunocompromised patients. The most common presentation is an atypical, chronic skin and soft tissue infection. Due to its high resistance rate, early diagnosis based on clinical suspicion, risk factor assessment, and exposure history is crucial for initiating appropriate multi-drug treatment. Methods: We report two cases of M. chelonae skin and soft tissue infections, one presenting with localized disease and the other with disseminated involvement. One case had a specific exposure to fish-related activities, a risk factor more commonly associated with Mycobacterium marinum infections rather than M. chelonae. Results: One of the cases involved osteomyelitis and tenosynovitis which are rare presentations of M. chelonae infection. While the limbs are the most commonly affected sites in disseminated M. chelonae infections, involvement of the lower extremities, as seen in one of our cases, is rarely reported. Treatment posed challenges due to antibiotic resistance and patient tolerance. However, in both cases where follow up was possible, prolonged multi-drug therapy led to complete resolution of the lesions. Conclusions: These cases highlight the importance of considering M. chelonae in chronic skin and soft tissue infections, especially in patient with relevant exposures or immunosupression. Uncommon presentations require a high index of suspicion. Given the challenges of treatment resistance and patient tolerance, prolonged multi-drug therapy remains essential for successful outcomes.
Full article
(This article belongs to the Section Tuberculosis and Mycobacteriosis)
►▼
Show Figures

Figure 1
Open AccessReview
Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques
by
Julien A. Clain, Morgane Picard, Henintsoa Rabezanahary, Sonia André, Steven Boutrais, Ella Goma Matsetse, Juliette Dewatines, Quentin Dueymes, Elise Thiboutot, Gina Racine, Calaiselvy Soundaramourty, Fabrizio Mammano, Pierre Corbeau, Ouafa Zghidi-Abouzid and Jérôme Estaquier
Infect. Dis. Rep. 2025, 17(1), 12; https://doi.org/10.3390/idr17010012 - 6 Feb 2025
Abstract
Background/Objectives: Over the last decades, our projects have been dedicated to clarifying immunopathological and virological events associated with Human Immunodeficiency Virus (HIV) infection. Methods: By using non-human primate models of pathogenic and non-pathogenic lentiviral infections, we aimed at identifying the cells and tissues
[...] Read more.
Background/Objectives: Over the last decades, our projects have been dedicated to clarifying immunopathological and virological events associated with Human Immunodeficiency Virus (HIV) infection. Methods: By using non-human primate models of pathogenic and non-pathogenic lentiviral infections, we aimed at identifying the cells and tissues in which the virus persists, despite antiretroviral therapy (ART). Indeed, the eradication of viral reservoirs is a major challenge for HIV cure. Results: We present a series of results performed in rhesus macaques of Chinese origin deciphering the virological and immunological events associated with ART that can be of interest for people living with HIV. Conclusions: This model could be of interest for understanding in whole body the clinical alteration that persist despite ART.
Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Infectious Diseases)
►▼
Show Figures

Figure 1
Open AccessArticle
Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital
by
Virginia Di Bari, Carlotta Cerva, Raffaella Libertone, Serena Maria Carli, Maria Musso, Delia Goletti, Alessandra Aiello, Antonio Mazzarelli, Angela Cannas, Giulia Matusali, Fabrizio Palmieri, Gina Gualano and on behalf of the TB-INMI Working Group
Infect. Dis. Rep. 2025, 17(1), 11; https://doi.org/10.3390/idr17010011 - 5 Feb 2025
Abstract
►▼
Show Figures
Background/Objectives: Tuberculosis (TB) remains a major global health issue, further complicated by the COVID-19 pandemic. This study assesses the clinical outcomes of TB-COVID-19-coinfected patients compared to those with TB disease alone at an Italian infectious disease hospital during the pandemic’s first two years.
[...] Read more.
Background/Objectives: Tuberculosis (TB) remains a major global health issue, further complicated by the COVID-19 pandemic. This study assesses the clinical outcomes of TB-COVID-19-coinfected patients compared to those with TB disease alone at an Italian infectious disease hospital during the pandemic’s first two years. Methods: Retrospective data analysis was conducted on TB patients hospitalized from March 2020 to June 2022. Data included demographics, comorbidities, clinical characteristics, and outcomes. Coinfection was defined as concurrent TB disease and SARS-CoV-2 infection. Statistical methods included Fisher’s exact test and Mann–Whitney statistics. Results: Of 267 TB patients, 25 (9.4%) had concurrent COVID-19 infection. The TB-COVID-19 group showed higher rates of diabetes and cough. Acute respiratory failure was more prevalent in coinfected patients (odds ratio, 5.99), and coinfection was associated with worse outcomes compared to TB alone (odds ratio, 0.15). Despite similar socio-demographic factors, the coexistence of TB and COVID-19 led to exacerbated respiratory failure and increased mortality. Conclusions: Coinfection with TB and COVID-19 significantly increases the risk of acute respiratory failure and poor outcomes. Clinicians should be aware of this risk, especially in patients with pulmonary involvement. Although specific protocols are unavailable, prompt diagnosis and management may enhance outcomes. Additional research is necessary to understand the long-term effects of TB-COVID-19 coinfection, particularly as COVID-19 becomes endemic.
Full article

Figure 1
Open AccessArticle
Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram-Negative Infections—Preliminary Study
by
Alexander Utrata, Niklas Schmidtner, Patricia Mester, Stephan Schmid, Martina Müller, Vlad Pavel and Christa Buechler
Infect. Dis. Rep. 2025, 17(1), 10; https://doi.org/10.3390/idr17010010 - 28 Jan 2025
Abstract
Background/Objectives: Men are more susceptible to sepsis than women, but the underlying pathways have not been fully clarified. Lipopolysaccharide-binding protein (LBP) is an acute-phase protein that is highly elevated in sepsis. Experimental evidence shows that LBP increases to a much greater extent in
[...] Read more.
Background/Objectives: Men are more susceptible to sepsis than women, but the underlying pathways have not been fully clarified. Lipopolysaccharide-binding protein (LBP) is an acute-phase protein that is highly elevated in sepsis. Experimental evidence shows that LBP increases to a much greater extent in male than in female mice following exposure to lipopolysaccharide. However, gender-specific studies of circulating LBP levels in sepsis patients are scarce. Methods: In the plasma of 189 patients with systemic inflammatory response syndrome (SIRS), sepsis, and septic shock, LBP levels were measured by enzyme-linked immunosorbent assay. Results: Patients with liver cirrhosis had reduced circulating LBP levels, regardless of gender. Further analysis within the non-cirrhotic patients showed no significant differences in LBP levels between sexes in patients with SIRS, sepsis, and septic shock. Ventilation, dialysis, and vasopressor therapy had no effect on LBP levels in either sex. A positive correlation between LBP and C-reactive protein was observed in the total cohort, males, and females. Infection with Gram-negative or Gram-positive bacteria had no effect on plasma LBP levels in males. However, female patients with Gram-negative infection had increased plasma LBP levels compared to females with negative and Gram-positive blood cultures, and 70 µg/mL LBP discriminates Gram-negative infections in females with a sensitivity of 88% and a specificity of 74%. Infection with SARS-CoV-2 did not change plasma LBP levels in either men or women. Female patients who did not survive had lower plasma LBP levels compared to female survivors and male non-survivors. Conclusions: This investigation highlights the influence of sex on plasma LBP levels in SIRS/sepsis patients, suggesting that LBP could be a sex-specific biomarker in critically ill patients.
Full article
(This article belongs to the Section Infection Prevention and Control)
►▼
Show Figures

Figure 1
Open AccessArticle
Mpox Cases in Serbia, 2022
by
Petar Đurić, Verica Jovanović, Mitra B. Drakulović, Dragana Plavša, Jovan Malinić, Aleksandar Medarević, Jelena Protić and Nana Mebonia
Infect. Dis. Rep. 2025, 17(1), 9; https://doi.org/10.3390/idr17010009 - 27 Jan 2025
Abstract
►▼
Show Figures
Background: On 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022. Methods:
[...] Read more.
Background: On 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022. Methods: The mpox WHO case definition was used. Incidence rates (IRs) and incidence rate ratios (IRRs) by age groups and nomenclature of territorial units for statistics level 3 (NUTS-3) with 95% confidence intervals (CIs) were calculated. Results: Between June and October 2022, 43 laboratory-confirmed cases were reported. All were unvaccinated males, with the mean age of 34 (±7.4) years. Out of the total, 72.1% cases were men who have sex with men (MSM), who reported sexual intercourse either with multiple or unknown partners (p < 0.01). Fifteen cases (34.9%) lived with HIV, mostly in the 30–39 age group (p = 0.023). People living in Belgrade City NUTS-3 were six times more likely to become infected compared to South Backa citizens (IRR: 6.03, 95% CI: 1.47–25.53). Conclusions: In Serbia, mpox mainly affected MSM aged 30–39 and living in urban areas. Health promotion and vaccine implementation should be prioritized in populations with a higher risk.
Full article

Figure 1
Open AccessArticle
Cytomegalovirus Blood DNAemia in Patients with Severe SARS-CoV-2 Pneumonia
by
Jean-Baptiste Mesland, Christine Collienne, Virginie Montiel, Alexis Werion, Philippe Hantson, Xavier Wittebole, Pierre-François Laterre and Ludovic Gerard
Infect. Dis. Rep. 2025, 17(1), 8; https://doi.org/10.3390/idr17010008 - 26 Jan 2025
Abstract
Introduction: Cytomegalovirus (CMV) DNAemia has been described in critically ill patients, including patients with severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) infection. Our objective is to evaluate the prevalence and clinical impact of CMV DNAemia among patients undergoing invasive mechanical ventilation (IMV) for severe SARS-CoV-2
[...] Read more.
Introduction: Cytomegalovirus (CMV) DNAemia has been described in critically ill patients, including patients with severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) infection. Our objective is to evaluate the prevalence and clinical impact of CMV DNAemia among patients undergoing invasive mechanical ventilation (IMV) for severe SARS-CoV-2 infection and to explore the association between CMV DNAemia levels and clinical outcomes. Methods: In this retrospective monocentric study, we included patients admitted in a tertiary ICU for severe COVID-19 and who required IMV. We aimed to compare clinical and demographic variables between patients with and without CMV DNAemia. Univariate and Cox regression analyses were performed to identify factors associated with CMV DNAemia. Results: During the study period, CMV blood DNAemia occurred in 30/135 patients (22%). Patients with CMV blood DNAemia had longer ICU and hospital length of stay, as well as longer duration of IMV, and were more likely to have received dexamethasone. However, there was no significant difference in ICU mortality between patients with and without CMV DNAemia (64.8% vs. 56.7%, p = 0.42). The Cox regression analysis showed that dexamethasone was the only factor independently associated with CMV blood DNAemia (HR 4.23 [1.006–17.792], p = 0.049). Conclusions: In patients with severe SARS-CoV-2 pneumonia requiring IMV, CMV DNAemia is common and associated with prolonged ventilation and increased LOS but not with increased mortality.
Full article
(This article belongs to the Topic Post COVID-19: Latest Advances, Challenges and Methodologies)
►▼
Show Figures

Figure 1
Open AccessArticle
Safety and Efficacy of a 48-Month Efinaconazole 10% Solution Treatment/Maintenance Regimen: 24-Month Daily Use Followed by 24-Month Intermittent Use
by
Aditya K. Gupta and Elizabeth A. Cooper
Infect. Dis. Rep. 2025, 17(1), 7; https://doi.org/10.3390/idr17010007 - 13 Jan 2025
Abstract
Background/Objectives: In an 18- to 24-month Treatment Phase with once-daily efinaconazole 10% solution, subjects with onychomycosis showed an increased rate of cure at Month 24 versus the phase III trials. In order to further improve efficacy, we initiated an extended intermittent efinaconazole Maintenance
[...] Read more.
Background/Objectives: In an 18- to 24-month Treatment Phase with once-daily efinaconazole 10% solution, subjects with onychomycosis showed an increased rate of cure at Month 24 versus the phase III trials. In order to further improve efficacy, we initiated an extended intermittent efinaconazole Maintenance Phase with use 2–3 times weekly for an additional 24 months from Month 24 to Month 48. These are the first data presented for a 48-month efinaconazole use period. Methods: For patients completing 18–24 months of once-daily efinaconazole, the target great toenail from the Treatment Phase was graded as ‘Clinical Cure’ (≤10% affected area) or ‘No Clinical Cure’ (>10% affected area) at Month 24. Mycological and clinical outcomes were assessed every 4 months from Month 24 to Month 48. There were 35 patients who enrolled in the extension and continued intermittent efinaconazole use to Month 48. Patients with ‘Clinical Cure’ at M24 were reviewed for sustained cure at M48; patients with ‘No Clinical Cure’ were reviewed for development of ‘Cure’ at M48. All patients were reviewed at all visits for adverse events that may be related to efinaconazole use. Results: ‘Clinical Cure’ was found in 6 of 35 enrolled patients at Month 24, and clinical cure status was sustained to Month 48 with intermittent efinaconazole maintenance use. For 29 patients with ‘No Clinical Cure’, 3/29 achieved ‘Clinical Cure’ status at Month 48 with intermittent efinaconazole. Effective Cure and Complete Cure rates improved over the maintenance period to Month 48 in subjects without clinical cure at Month 24. Younger patients showed higher cure rates over the maintenance period, but age group cure differences did not reach statistical significance in this dataset, and 49% of the ≥70-year population had at least a 20% reduction in nail area with maintenance therapy to Month 48. There was only 1 case of possible efinaconazole application site reaction in the Intermittent Maintenance Period to Month 48; prolonged efinaconazole use to Month 48 does not appear to increase the risk of reaction. Efinaconazole use periods are associated with very low positive culture rates in this dataset, including typical contaminant organisms, suggesting efinaconazole presence in the nail plate is providing prophylactic therapy. Conclusions: Intermittent efinaconazole may provide suitable prophylaxis of onychomycosis relapse. Prolonged efinaconazole therapy to Month 48 appears to be safe for all ages and can continue to provide prophylaxis of onychomycosis with Intermittent Maintenance use beyond Month 24 to Month 48.
Full article
(This article belongs to the Section Fungal Infections)
►▼
Show Figures

Figure 1
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Infectious Disease Reports, Insects, IJERPH, Pathogens, TropicalMed, Zoonotic Diseases
Vector-Borne Disease Spatial Epidemiology, Disease Ecology, and Zoonoses
Topic Editors: Chad L. Cross, Louisa Alexandra MessengerDeadline: 31 December 2025

Conferences
Special Issues
Special Issue in
Infectious Disease Reports
Prevention, Diagnosis and Treatment of Infectious Diseases
Guest Editors: Marc Ouellette, Rabeea Omar, Sachiko SatoDeadline: 31 March 2025
Special Issue in
Infectious Disease Reports
Emerging and Reemerging Infections of the Central Nervous System
Guest Editor: Sofia R. ValdoleirosDeadline: 30 April 2025
Special Issue in
Infectious Disease Reports
Epidemiology, Prevention and Research on Dengue Virus
Guest Editor: Alessandro BartoloniDeadline: 31 May 2025
Special Issue in
Infectious Disease Reports
Viral Infectious Diseases: Epidemiology and Prevention through Vaccination
Guest Editor: George RachiotisDeadline: 31 August 2025